Companion Diagnostics Market to Hit US$
4,786 Million by 2032, Driven by
Personalized Medicine
New York, NY – June 18, 2025 - The global companion diagnostics (CDx) market is
projected to reach US$ 4,786 million by 2032, growing from USD 2,452 million in 2022.
This reflects a steady CAGR of 7.1% from 2022 to 2032. One of the main drivers of this
market is the rising demand for personalized medicine.
The increasing global cancer burden is another strong growth factor for the companion
diagnostics market. As per the World Health Organization (WHO), cancer caused nearly 10
million deaths in 2020. Modern cancer treatments often require genetic testing to identify
eligible patients. CDx tests are used to detect specific mutations, guiding physicians in
choosing the right drug. This integration of diagnostics with oncology treatments supports
precise, patient-specific care. The growing need for early and accurate cancer diagnosis has
made CDx tools a standard component in many treatment plans.
Government support and regulatory clarity are also helping this sector grow. Regulatory
bodies like the FDA and the European Medicines Agency (EMA) have provided clear
frameworks for the co-development of drugs and companion diagnostics. This has
encouraged pharmaceutical companies to invest in CDx development alongside their new
therapies. Examples include FDA-approved tests for cancer drugs such as trastuzumab and
osimertinib. These approvals have made it easier for patients to receive treatments tailored to
their genetic profiles, speeding up adoption among healthcare providers.
Technological advancements in genetic testing have played a crucial role in expanding the
CDx market. Innovations such as next-generation sequencing (NGS) allow the testing of
multiple genes quickly and accurately. These methods save time, reduce costs, and improve
precision. The Centers for Disease Control and Prevention (CDC) has emphasized the value
of genomics in improving public health outcomes. This focus has led to wider use of
advanced diagnostics across not just oncology but also other areas like rare and chronic
diseases.
Lastly, awareness among both patients and healthcare providers is on the rise. As knowledge
about genetic-based treatment options increases, more patients are requesting personalized
care. Hospitals and clinics are also integrating CDx tools to enhance treatment outcomes. The
growing shift towards precision medicine, supported by better tools, policies, and education,
is expected to drive long-term growth in the companion diagnostics sector.
Key Takeaways





According to recent analysis, the global companion diagnostics market is expected to
exceed US$ 4,786 million by the year 2032.
Back in 2022, the same market was valued at around US$ 2,452 million, showing
strong growth momentum over the past years.
Experts report that the companion diagnostics market is expanding steadily at a
compound annual growth rate (CAGR) of 7.1%.
North America dominated the companion diagnostics market in 2022, capturing a
leading revenue share of nearly 43%.
Europe followed as the second-largest market, holding a revenue share of
approximately 25% during the same year.
Emerging Trends
Shift Toward Personalized Medicine
More healthcare providers now prefer treatments tailored to each patient. Companion
diagnostics (CDx) play a key role in this change. These tests help doctors choose the right
drug based on a person’s genes or the exact type of disease. Instead of using a single
treatment for everyone, CDx allows for custom care. This increases the chances of better
results and fewer side effects. Personalized medicine is no longer just a trend—it is becoming
the standard. As more doctors and labs use these tools, patient care is getting smarter and
more focused.
Increased Focus on Cancer Treatments
Cancer is the leading driver behind the rise of companion diagnostics. Many CDx tests are
now being designed for cancers such as lung, breast, colon, and melanoma. These tests help
identify which patients will respond well to specific targeted therapies. This makes treatment
more effective and avoids drugs that may not work. As new cancer drugs enter the market,
matching diagnostics are developed alongside them. This strong link between oncology and
CDx is pushing major innovation. Cancer patients now have more precise treatment options
than ever before.
Expansion Beyond Oncology
While cancer remains the biggest area of focus, companion diagnostics are expanding into
other diseases. New CDx tools are now being researched for HIV, cardiovascular diseases,
and autoimmune conditions. This wider use of CDx means more patients in different
specialties can benefit from personalized care. Doctors in these fields can soon use genetic
and biomarker data to guide treatment choices. This shift opens new doors for better
diagnosis and patient-specific therapies. As research grows, the scope of CDx is no longer
limited to just cancer.
Use of Liquid Biopsy Technology
Liquid biopsy is a major advancement in the CDx space. Unlike traditional biopsies, this
method only requires a blood sample. It’s less painful and easier for patients. Liquid biopsies
are now being used to monitor how diseases progress and how well treatments are working.
This non-invasive approach is gaining more trust in the medical community. It also allows for
more frequent testing, making disease tracking more accurate. As this technology improves,
it is becoming a strong alternative to tissue biopsies in companion diagnostics.
Growing Role of AI and Machine Learning
Artificial intelligence (AI) is changing how companion diagnostics are developed. With
machine learning, large sets of patient data can be analyzed faster and with greater accuracy.
AI helps researchers discover new biomarkers and fine-tune diagnostic tools. It can also
predict how well a treatment may work for a certain patient group. This reduces the time
needed for research and improves test performance. As AI becomes more advanced, its role
in CDx is expected to grow even further. This will lead to faster, smarter, and more reliable
diagnostics.
Use Cases
Targeted Cancer Therapy
In lung cancer, companion diagnostics (CDx) are often used to test for gene mutations like
EGFR. This mutation helps the tumor grow. If the EGFR mutation is found, doctors can give
a drug that blocks it. This targeted approach helps stop the cancer from growing. Without
CDx, doctors may give a drug that doesn’t work well. Instead of guessing, CDx gives clear
answers. It matches the patient with a drug made just for their type of cancer. This improves
the chances of success and limits unnecessary side effects. It’s a smarter, more focused way
to treat cancer patients from the very beginning.
Predicting Drug Effectiveness
Every patient responds differently to medicine. Some drugs work well for one person but not
for another. In some cases, a drug may even cause harmful side effects. CDx helps avoid this
problem. It uses genetic information to predict how well a drug will work. If a drug is likely
to fail or cause issues, doctors can choose a better option. This saves patients from trial-anderror treatments. It also reduces wasted time and cost. CDx makes sure patients get the right
treatment, faster. It’s all about finding what works best for the individual, not the average
person.
Monitoring Drug Response
Treatment doesn't always go as planned. Sometimes a drug that looks promising may not
work as expected. CDx helps monitor the patient’s response during treatment. It can show if
the drug is working or not. If the results are poor, doctors can change the therapy quickly.
This helps avoid delays in care. It also reduces the chance of the disease getting worse. By
tracking drug response in real-time, CDx helps improve patient outcomes. It gives doctors
useful data to make better choices. Patients benefit by getting effective care without
unnecessary waiting or suffering.
Detecting Drug Resistance
Over time, some treatments stop working. This can happen when the cancer becomes
resistant to a drug. CDx can detect resistance before symptoms appear. It finds new mutations
that block the drug’s effect. When resistance is caught early, doctors can change the treatment
quickly. This keeps the disease from progressing. Patients get a new plan based on updated
results. It also helps avoid continuing a treatment that no longer works. CDx gives doctors the
tools to stay ahead of the disease. Early action leads to better care, fewer side effects, and
more hope for the patient.
Guiding Clinical Trials
Drug companies use CDx to choose the right people for clinical trials. Not every drug works
for every person. CDx helps find patients who are most likely to benefit. This makes trials
faster and more effective. It improves the chances of a new drug getting approved. Patients in
the trial also have a better shot at getting a treatment that works. CDx speeds up research and
reduces costs. It helps make new therapies available sooner. For both companies and patients,
using CDx in clinical trials is a win-win. It supports innovation and better health outcomes.
Conclusion
The companion diagnostics market is becoming more important in modern healthcare. As the
demand for personalized medicine grows, CDx tools are helping doctors choose better
treatments based on a patient’s unique genetic profile. These diagnostics are especially useful
in cancer care but are now expanding into other areas like heart disease and autoimmune
conditions. Support from governments, better technologies like liquid biopsy, and the use of
artificial intelligence are pushing the market forward. Hospitals, clinics, and pharmaceutical
companies are adopting CDx more than ever. With improved accuracy and patient-focused
care, companion diagnostics are set to play a key role in the future of treatment and medical
research.